Merve Keskinkilic | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award

Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey

Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.

Publication Profile

Scopus

Scholar

🎓 Education

Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).

💼 Experience

Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.

🏆 Awards & Honors

Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.

🔬 Research Focus

Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.

Publication Top Notes

  • Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
    • Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
    • Journal: BMC Cancer, 2023
    • Citations: 20

 

  • Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    • Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
    • Journal: Future Oncology, 2023
    • Citations: 13

 

  • Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
    • Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
    • Journal: The Breast, 2022
    • Citations: 13

 

  • The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
    • Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
    • Journal: The Breast, 2023
    • Citations: 12

 

  • Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
    • Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
    • Journal: Journal of Chemotherapy, 2024
    • Citations: 4

 

  • The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
    • Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
    • Journal: Future Oncology, 2023
    • Citations: 4

 

  • Antibody-Drug Conjugates in Triple Negative Breast Cancer
    • Authors: M. Keskinkilic, R. Sacks
    • Journal: Clinical Breast Cancer, 2024
    • Citations: 3

 

  • 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
    • Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
    • Journal: Annals of Oncology, 2022
    • Citations: 3

 

  • The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
    • Authors: H. I. Ellez, M. Keskinkilic, et al.
    • Journal: Journal of Clinical Medicine, 2023
    • Citations: 11

 

  • The role of immune checkpoint inhibition in triple-negative breast cancer
    • Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
    • Journal: Expert Review of Anticancer Therapy, 2023
    • Citations: 10

 

  • The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
    • Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2023
    • Citations: 5

 

  • CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
    • Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
    • Journal: The Prostate, 2022
    • Citations: 5

 

  • A severe case of levothyroxine intoxication successfully treated in intensive care unit
    • Authors: Y. Savran, T. Mengi, M. Keskinkilic
    • Journal: Journal of Acute Disease, 2018
    • Citations: 11

 

 

Ashwani Patil | Cancer Biology | Best Scholar Award

Posted on by ScienceFather

Dr. Ashwani Patil | Cancer Biology | Best Scholar Award

Assistant Professor, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research India

Dr. Ashwani Patil is a passionate pharmacologist specializing in neurological disorders and cancer research. He completed his Ph.D. in Pharmacology from the Institute of Chemical Technology (ICT), Mumbai, with a focus on preclinical drug development. His research at Bhabha Atomic Research Centre and NIRRH Mumbai deepened his expertise in molecular mechanisms underlying complex diseases. With hands-on experience in animal handling, molecular techniques, and pharmacological testing, he has contributed significantly to understanding disease pathology and potential therapeutic targets for cancer and neurological disorders.

Professional Profile 

Scopus

Scholar

🎓Education

Ph.D. in Pharmaceutical Tech. (Pharmacology), Institute Of Chemical Technology, Mumbai (2024). M. Pharmacy (Pharmacology), R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018). Bachelor of Pharmacy, A.R.A College of Pharmacy, Dhule (2016)

💼Experience

Junior Research Fellow, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018-2019). Research Scholar, Institute of Chemical Technology, Mumbai (2022-Present). Assistant Professor, Dr. D Y Patil Institute of Pharmaceutical Science and Research, Pune (2019-2020, 2024). Expertise in preclinical drug studies, rodent surgery, data analysis, and project planning.

🏆Award and Honor

DAE-ICT Fellowship, 2024. 1st Position in Poster Presentation, 7th International Conference on “Emerging Trends in Drug Development and Delivery” (2024). Research Excellence Award, GEU, Dehradun (2015). Best Paper Presentation Award, TriboIndia 2023, NIT Srinagar

🔬 Research Focus

Dr. Patil’s research spans preclinical drug development, focusing on neurological disorders and cancer. His work investigates therapeutic targets, pharmacodynamics, and the molecular mechanisms of disease pathology. Key areas of interest include rodent models, drug efficacy, safety profiles, and mitochondrial toxicity. His publications highlight cancer cell cytotoxicity and cardioprotective effects, contributing to the understanding of pharmacological agents in disease treatment.

Publications Top Noted

1. Title: Cardioprotective effect of CB1 receptor antagonist AM251 against β receptor-stimulated myocardial infarction via modulation of NF-kB signaling pathway in diabetic mice

Year: 2024
Authors: Pawar, H.D., Patil, Y., Patil, A., Ojha, S., Goyal, S.N.
Citation: Heliyon, 10(15), e35138
Citations: 0

2. Title: Mitochondria-targeted derivative of pterostilbene, a dietary phytoestrogen, exhibits superior cancer cell cytotoxicity via mitochondrial superoxide mediated induction of autophagy

Year: 2023
Authors: Ibrahim, M.K., Nandha, S.R., Patil, A.S., Sharma, D., Sandur, S.K.
Citation: Advances in Redox Research, 8, 100071
Citations: 1

3. Title: Mitochondriotropic Derivative of Ethyl Ferulate, a Dietary Phenylpropanoid, Exhibits Enhanced Cytotoxicity in Cancer Cells via Mitochondrial Superoxide-Mediated Activation of JNK and AKT Signalling

Year: 2023
Authors: Patil, A.S., Ibrahim, M.K., Sathaye, S., Sharma, D., Sandur, S.K.
Citation: Applied Biochemistry and Biotechnology, 195(3), 2057–2076
Citations: 2

4. Title: Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: A review

Year: 2020
Authors: Patil, A.S., Mahajan, U.B., Agrawal, Y.O., Sharma, C., Goyal, S.N.
Citation: Biomedicine and Pharmacotherapy, 132, 110889
Citations: 17

5. Title: Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats

Year: 2019
Authors: Patil, A.S., Singh, A.D., Mahajan, U.B., Ojha, S., Goyal, S.N.
Citation: Molecular and Cellular Biochemistry, 456(1-2), 105–113
Citations: 17

 

Jessica Abene| Oncology| Best Researcher Award

Posted on by ScienceFather

Ms. Jessica Abene| Oncology| Best Researcher Award

Ms. University of Pennsylvania,  United States

Jessica Abene is a dedicated nursing professional with a passion for advancing healthcare through evidence-based research. She earned her Bachelor of Nursing Science (BSN) from the University of Pennsylvania in 2023 and is currently pursuing a Master’s in Statistics and Data Science, as well as a PhD. Jessica is deeply engaged in research focused on improving patient care, particularly in oncology and eating disorders. She is an author of several publications, including systematic reviews on chemotherapy toxicities, food insecurity, and binge eating. Her expertise extends to clinical trials and the development of innovative healthcare solutions, such as a smart swaddle for infants with neonatal abstinence syndrome. Jessica is committed to improving patient quality of life through her work as a graduate research assistant and peer reviewer.

Profile

Scopus

🎓 Education

University of Pennsylvania Bachelor of Nursing Science (BSN), 2023. Master of Statistics and Data Science, In Process. Doctor of Philosophy, In Process

💼 Experience

Graduate Research Assistant, University of Pennsylvania, 2021-Present Jessica leads research on diet interventions to alleviate chemotherapy toxicities, coordinates data for clinical trials, and manages a systematic review on food insecurity and binge eating. Peer Reviewer, European Journal of Oncology Nursing, 2024-Present Evaluates submissions for scientific rigor, providing feedback to improve clarity and validity. Penn Nursing Innovation Accelerator Awardee, 2022 Led a team to develop a smart swaddle for infants with neonatal abstinence syndrome, offering comfort and distress relief.

🏆 Awards & Honors

Best Review Paper, International Journal of Eating Disorders (2023) Recognized for outstanding scholarly work as an early career scholar. Rita and Alex Hillman Foundation Pilot Award ($5,000) Awarded for innovative healthcare research. Doctoral Student Organization Research Grant ($325) Provided funding to support academic research. Penn Nursing Innovation Accelerator Awardee ($2,500) Awarded for leading an innovation team developing a smart swaddle system. Eastern Nursing Research Society Annual Conference Abstract Presentation (2023) Presented impactful research findings.

🔬 Research Focus

Jessica’s research aims to improve patient outcomes through evidence-based interventions. She is particularly focused on the impact of diet on chemotherapy toxicities and quality of life, as well as the relationship between food insecurity and binge eating disorders. Additionally, she coordinates clinical trials and studies exploring the effects of lymphedema and fibrosis treatment. Her innovative work includes developing a smart swaddle system for infants with neonatal abstinence syndrome (NAS). Jessica’s research seeks to create practical solutions for complex health challenges and contribute to enhancing patient care in diverse clinical settings.

🏆Conclusion 

Jessica Abene’s combination of rigorous academic training, innovative research, and leadership in healthcare makes her a standout candidate for the Best Researcher Award. Her systematic reviews, dedication to improving patient quality of life, and groundbreaking work in the intersection of healthcare and technology reflect her potential to make significant contributions to the nursing field. Continuing to expand her research network and engaging more broadly with the community will further enhance her already impressive career trajectory.

Publication

  • Dietary Interventions for Alleviating Chemotherapy Toxicities in Patients with Cancer: A Systematic Review
    Year: 2024
    Authors: Abene, J. & Deng, J.
    Status: In process

 

  • Diet as an Adjunct Therapy in Reducing Chemotherapy Toxicities and Improving Patients’ Quality of Life: A Systematic Review and Meta-Analysis
    Year: 2024
    Authors: Abene, J., Tyburski, S., Kral, T. V. E., Quinn, R., & Deng, J.
    Journal: Nutrition and Cancer, 1–19
    DOI: 10.1080/01635581.2024.2437833

 

  • Food Insecurity and Binge Eating: A Systematic Review and Meta-Analysis
    Year: 2023
    Authors: Abene, J. A., Tong, J., Minuk, J., Lindenfeldar, G., Chen, Y., & Chao, A. M.
    Journal: The International Journal of Eating Disorders, 56(7), 1301–1322

 

  • Binge Eating Disorder and Eating Self-Efficacy in Adults Seeking Bariatric Surgery
    Year: 2022
    Authors: Chao, A. M., Abene, J., Allison, K. C., Pearl, R. L., Wadden, T. A., Williams, N. N., & Tronieri, J. S.
    Journal: Clinical Obesity, e12531
    DOI: 10.1111/cob.12531

 

  • The Importance of Student Nursing and Engineering Collaborations
    Year: 2022 (May 20)
    Authors: Leary, M., Abene, J.
    Journal: American Nurse